CN116376844B - HER2 positive tumor targeting CAR-T containing SHP2 SH2 domain, preparation method and application - Google Patents
HER2 positive tumor targeting CAR-T containing SHP2 SH2 domain, preparation method and application Download PDFInfo
- Publication number
- CN116376844B CN116376844B CN202310627430.5A CN202310627430A CN116376844B CN 116376844 B CN116376844 B CN 116376844B CN 202310627430 A CN202310627430 A CN 202310627430A CN 116376844 B CN116376844 B CN 116376844B
- Authority
- CN
- China
- Prior art keywords
- domain
- car
- shp2
- seq
- her2 positive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 30
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 title claims abstract description 22
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 title claims abstract description 22
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 title claims abstract description 17
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 title claims abstract description 17
- 230000008685 targeting Effects 0.000 title claims abstract description 11
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 230000003834 intracellular effect Effects 0.000 claims abstract description 8
- 239000002773 nucleotide Substances 0.000 claims abstract description 5
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 5
- 108020001580 protein domains Proteins 0.000 claims abstract description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 14
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 230000000139 costimulatory effect Effects 0.000 claims description 4
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 3
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 3
- 102000003960 Ligases Human genes 0.000 claims description 3
- 108090000364 Ligases Proteins 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 230000005540 biological transmission Effects 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 230000001506 immunosuppresive effect Effects 0.000 claims description 3
- 201000002313 intestinal cancer Diseases 0.000 claims description 3
- 108091008146 restriction endonucleases Proteins 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 238000012163 sequencing technique Methods 0.000 claims description 3
- 230000011664 signaling Effects 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 230000009466 transformation Effects 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 230000000903 blocking effect Effects 0.000 claims description 2
- 238000001976 enzyme digestion Methods 0.000 claims description 2
- 239000013600 plasmid vector Substances 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 230000014509 gene expression Effects 0.000 abstract description 4
- 238000011160 research Methods 0.000 abstract description 3
- 101100065582 Arabidopsis thaliana ERF071 gene Proteins 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 36
- 210000004881 tumor cell Anatomy 0.000 description 18
- 230000002147 killing effect Effects 0.000 description 17
- 239000000243 solution Substances 0.000 description 7
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 6
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 241000700605 Viruses Species 0.000 description 5
- 102000007607 Non-Receptor Type 11 Protein Tyrosine Phosphatase Human genes 0.000 description 4
- 108010032107 Non-Receptor Type 11 Protein Tyrosine Phosphatase Proteins 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 3
- 102000014400 SH2 domains Human genes 0.000 description 3
- 108050003452 SH2 domains Proteins 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 3
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- DCWXELXMIBXGTH-QMMMGPOBSA-N phosphonotyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-QMMMGPOBSA-N 0.000 description 2
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 2
- 108010056030 retronectin Proteins 0.000 description 2
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 108700020302 erbB-2 Genes Proteins 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000005283 ground state Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical group OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Abstract
The invention belongs to the field of cell biology, and particularly relates to a HER2 positive tumor targeting CAR-T containing an SHP2 SH2 domain, a preparation method and application thereof, which are used for relieving the problem of poor curative effect of HRE2 positive expression solid tumors in the existing research. The CAR-T extracellular domain is a nanobody targeting HER2 positive tumor, and the intracellular domain comprises an SHP2 protein domain; the SHP2 protein structural domain is an N+C-SH2 structural domain, and the nucleotide sequence of the SHP2 protein structural domain is shown as SEQ ID NO. 1.
Description
Technical Field
The invention belongs to the field of cell biology, and particularly relates to a HER2 positive tumor targeting CAR-T containing an SHP2 SH2 domain, a preparation method and application thereof.
Background
Human epidermal growth factor receptor 2 (Human Epidermal Growth Factor Receptor, HER 2) is a cell-derived proto-oncogene, also known as the c-erbB-2 gene, that is overexpressed and amplified in a variety of tumors. The presence of excessive HER2 protein on the surface of tumor cells promotes the division and growth of tumor cells, thereby forming HER2 positive tumors. HER2 overexpression is common in tumors such as breast cancer, gastric cancer, intestinal cancer, and the like.
CAR-T cell (CAR-T for short) therapy (Chimeric Antigen Receptor T-Cell Immunotherapy) is fully called chimeric antigen receptor T cell immunotherapy, and is a novel accurate targeted therapy for treating tumors. The research shows that the CAR-T cells can accurately, quickly, efficiently and specifically identify and kill the tumor cells, and in recent years, the CAR-T cells have good effect on assisting in the treatment of tumors through optimization and improvement, so that the CAR-T cells are a very promising research direction for novel tumor immunotherapy which is possible to cure cancers. However, CAR-T therapies are currently still controversial in the effects of different tumors, especially solid tumors, which is a challenging goal of CAR-T therapies to overcome.
Src homology 2 domain protein tyrosine phosphatase (SHP 2) is a dephosphorylase belonging to the protein tyrosine phosphatase family. The full length of SHP2 consists of two SH2 domains (N-SH 2 and C-SH 2), a conserved PTP domain and a flexible C-terminal tail. The activity of the complete SHP2 phosphatase is regulated and controlled by the change of the conformation of the complete SHP2 phosphatase, and the N-SH2 domain is combined with the PTP domain in the ground state and directly blocks the active site of the complete SHP2 phosphatase, so that the complete SHP2 phosphatase maintains a self-inhibition conformation; when the signaling protein of SHP2 is activated by the signal of tumor cells, the upstream receptor tyrosine kinase (Receptor Tyrosine Kinase, RTK) triggers pTyr (phosphorylated tyrosine) residues on PD1 to bind to both SH2 domains of SHP2, releasing the PTP domains from the self-inhibited state, transmitting the downstream signal of activated PD1, thereby inhibiting T cell activity.
In summary, the present invention will provide a novel CAR-T with improved structure that specifically targets HER2 positive expressing tumor cells to complement the shortcomings of the current studies.
Disclosure of Invention
In view of the above, the main objective of the present invention is to provide a SHP2 SH2 domain-containing CAR-T targeting HER2 positive tumors, and a preparation method and application thereof, and the specific technical scheme is as follows.
A HER2 positive tumor-targeting CAR-T, the chimeric antigen receptor portion of which comprises an extracellular domain, a transmembrane domain and an intracellular domain, the extracellular domain being a nanobody (abbreviated as HER2 nanobody) that targets a HER2 positive tumor, the intracellular domain comprising a SHP2 protein domain; the SHP2 protein structural domain is an N+C-SH2 structural domain, and the nucleotide sequence of the SHP2 protein structural domain is shown as SEQ ID NO. 1.
Further, the nucleotide sequence of the chimeric antigen receptor is shown as SEQ ID NO. 2.
Further, the intracellular domain of the chimeric antigen receptor also includes a 4-1BB costimulatory molecule and a CD3 zeta truncating signal domain, wherein CD3 zeta is preferably truncated and comprises only the ITAM1 moiety.
Further, the chimeric antigen receptor also includes a CD8 hinge region.
Further, the CAR-T expresses the chimeric antigen receptor of any one of the above.
The application of the CAR-T in preparing an anti-tumor drug, wherein the SHP2N+C-SH 2 domain in the CAR-T is used for competitively combining with PD-1 to block the transmission of PD-1 and/or PD-L1 immunosuppression signals.
Further, the tumor is a solid tumor that HER2 expresses positively.
Further, the solid tumor comprises ovarian cancer, breast cancer, gastric cancer or intestinal cancer, etc.
The preparation method of the CAR-T comprises the following steps:
1) CAR structures including nanobodies targeting HER2 positive tumors, CD8 hinge region, transmembrane region, 4-1BB costimulatory molecule, CD3 ζ truncated signaling domain, shp2n+c-SH 2 domain were synthesized.
2) Respectively carrying out double enzyme digestion on the plasmid vector and the synthesized CAR structure by using restriction enzymes, carrying out transformation and screening culture after being connected by using T4 ligase, and carrying out sequencing identification on the obtained positive clone;
3) The synthesized CAR was bound to T cells.
Further, the primer sequences for amplifying the SHP2N+C-SH 2 domain are shown as SEQ ID NO. 3 and SEQ ID NO. 4.
Beneficial technical effects
The invention provides a novel CAR-T targeting HRE2 positive tumor cells with improved structure, wherein two SHP2 SH2 domains in the CAR-T structure can be used for competitively combining with PD-1 to block the transmission of PD-1 and/or PD-L1 immunosuppression signals, so that the immunocompetence state of T lymphocytes is maintained, and the tumor cells positively expressed by HER2 can be continuously kept to have a killing effect.
Second, although studies have now shown that the pTyr residues on PD1 can bind to both SH2 domains of SHP 2. However, the experiment proves that the single SHP2N+C-SH 2 fragment cannot exert ideal anti-tumor efficacy, and is characterized in that when the effective Target ratio E is T=1:1 (E represents Effector cell, i.e. Effector cell; T represents Target cell, i.e. tumor cell), after 24 hours of continuous killing, the CAR-T cell prepared by the invention can already show obvious effect of killing/killing tumor, but the single SHP2N+C-SH 2 fragment hardly exerts anti-tumor effect. It can be seen that the CAR-T cells prepared by the method have great potential in the field of immunotherapy.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below. It will be apparent to those of ordinary skill in the art that the drawings in the following description are of some embodiments of the invention and that other drawings may be derived from these drawings without inventive faculty.
FIG. 1 shows the synthesized CAR structure of the present invention (Her 2 VH-BBZ (short) -P2A-shp2n+c-SH 2) schematic;
FIG. 2 is a graph showing the results of the positive expression rate of the synthesized CAR according to the present invention (APC is a fluorescent dye, H represents height);
FIG. 3 is a graph of the in vitro killing (LDH) effect of CAR-T cells;
FIG. 4 is a graph showing the effect of continuous killing of tumor cells and CAR-T cells at an effective target ratio of 1:1;
FIG. 5 is a graph of statistical tumor cell to CAR-T cell continuous killing at an effective target ratio of 1:1;
fig. 6 shows that tumor cells and CAR-T cells were at 1:2.5, a continuous killing condition effect graph under the effective target ratio;
fig. 7 is a graph of statistical tumor cells versus CAR-T cells at 1:2.5, a plot of continuous killing at an effective target ratio;
fig. 8 shows that tumor cells and CAR-T cells were at 1:5, a continuous killing condition effect diagram under the effective target ratio;
fig. 9 is a graph of statistical tumor cells versus CAR-T cells at 1: graph of continuous killing at effective target ratio of 5.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present invention more clear, the technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings in the embodiments of the present invention. It will be apparent that the described embodiments are some, but not all, embodiments of the invention. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
It should be noted that, in this document, the terms "comprises," "comprising," or any other variation thereof, are intended to cover a non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements does not include only those elements but may include other elements not expressly listed or inherent to such process, method, article, or apparatus. Without further limitation, an element defined by the phrase "comprising one … …" does not exclude the presence of other like elements in a process, method, article, or apparatus that comprises the element.
As used in this specification, the term "about" is typically expressed as +/-5% of the value, more typically +/-4% of the value, more typically +/-3% of the value, more typically +/-2% of the value, even more typically +/-1% of the value, and even more typically +/-0.5% of the value.
In this specification, certain embodiments may be disclosed in a format that is within a certain range. It should be appreciated that such a description of "within a certain range" is merely for convenience and brevity and should not be construed as a inflexible limitation on the disclosed ranges. Accordingly, the description of a range should be considered to have specifically disclosed all possible sub-ranges and individual numerical values within that range. For example, the description of ranges 1-6 should be considered as having specifically disclosed sub-ranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6, etc., as well as individual numbers within such ranges, e.g., 1,2,3,4,5, and 6. The above rule applies regardless of the breadth of the range.
Example 1
The present example provides a method of preparing a CAR-T cell.
Construction of car expression vector:
1) The CAR structure consists of extracellular HER2 nano antibody, CD8 hinge region, transmembrane region, intracellular 4-1BB costimulatory molecule, CD3 zeta truncated signal domain and SHP2N+C-SH 2 structural domain, and the structural fragment is prepared by adopting a gene synthesis method.
2) The restriction endonucleases EcoR I and BamH I are used for respectively carrying out double digestion on the Pwpxld vector and the CAR structural fragment, T4 ligase is used for connection, transformation and screening culture are carried out, and the obtained positive clones are subjected to sequencing identification, so that the HER2 CAR-Pwpxld expression vector and the SHP2N+C-SH 2-Pwpxld control vector (the control vector only contains SHP2N+C-SH 2 fragments) are finally obtained. The CAR synthesized by the invention is totally called Her2 VH-BBZ (short) -P2A-SHP2N+C-SH 2, the structure of which is shown in FIG. 1.
The sequences of the fragments synthesized/amplified in this example are shown in Table 1.
TABLE 1
2. Lentivirus packaging:
1) And recovering and culturing 293T cells, and packaging the viruses when the fusion degree reaches about 80%.
2) Chloroquine solution was added to the medium (DMEM+10% FBS) to give a final concentration of 100. Mu. Mol/L.
3) The virus packaging system (10 cm dish) is: 50 μl CaCl 2 20. Mu.g of the constructed core plasmid, 10. Mu.g of Pspax2, 5. Mu.g of PMD2.0G, 500. Mu.l of nucleic-free wafer (Nuclease free water), 500. Mu.l of 2 XBBS.
4) Fresh pre-warmed medium (dmem+10% fbs) was changed for about 10 h.
5) The virus liquid cultured for 48 hours and 72 hours is collected, and the impurities are removed by filtration through a 0.22 mu m filter membrane.
6) Ultracentrifugation, re-suspending concentrated virus with DPBS 1/400 of virus stock, and sub-packaging at-80deg.C for use.
3. Peripheral blood cell separation:
1) T cell culture flasks (T25) were incubated one day in advance and overnight at 4 ℃. T cell culture medium contains anti-human CD3 and CD8D monoclonal antibodies: 3mL DPBS, 4. Mu.g/mL CD3, 4. Mu.g/mL CD28.
2) An appropriate amount of fresh blood was drawn from healthy volunteers.
3) A15 mL BD tube was taken, 5mL Ficoll was added, and 5mL fresh blood was gently added.
4) Centrifuging at normal temperature, and lifting by 1 to 1000g for 30min.
5) After centrifugation, the intermediate (white) peripheral blood lymphocytes are carefully aspirated.
6) Three volumes of pre-warmed DPBS were added for washing, 300g,10min.
7) Optionally 5mL of red blood cell lysate was added, lysed for 5min at room temperature, and an equal volume of pre-warmed DPBS was added.
8) Cell count, centrifuge at normal temperature, 100g,10min.
9) Appropriate amount of T cell culture medium (X-vivo, 5% AB serum, 400IU IL2) was added at 2X 10-6/mL to resuspend the cells.
10 The antibody incubation liquid in the T25 square bottle is sucked, the T cells resuspended by the T cell culture liquid are added, and the normal culture is carried out for about 48 hours at 37 ℃.
car-T cell preparation:
1) T cell culture plates were incubated one day in advance and overnight at 4 ℃. A24-well plate was used, and 0.5mL of DPBS and 10. Mu.l of Retronectin (1 mg/mL) were added to each well.
2) The RetroNectin solution was blotted off.
3) 1mL of 2% BSA solution was added to each well and the wells were blocked at 37℃for 30min.
4) The blocking solution was aspirated and washed once with DPBS.
5) Mu.l 400 Xvirus, 300. Mu. l X-vivo complete medium, 32℃and 1000g up and down 2 were added to each well (non-adherent well plate) and centrifuged for 2h.
6) 2-2.5X 10X 6T cells activated for 48h are added into each hole, the X-vivo complete culture medium is supplemented to 1 mL/hole, the temperature is 32 ℃, and the centrifugation is carried out for 15min by 300g 2 g.
7) The CAR positive expression rate is detected through flow after normal culture for about 72 hours at 37 ℃, and is shown in figure 2. The positive expression rate of the CAR synthesized by the invention is 78.0%.
Example 2
This example provides an in vitro kill test.
1) Killing of 96-well plates: tumor cells 1 x 10≡4/well, CAR-T cells constructed with the invention and control T cells with SHP2N+C-SH 2 alone were plated at 1:1, 2.5:1, 5:1 effective target ratio to tumor cells, 3 duplicate wells per effective target ratio, respectively, and blank T cell (Mock) controls were made.
This example uses the Skov3-mCherry cell line, a cell model with a broad representation.
2) And continuously detecting the in vitro killing condition of the CAR-T cells by using a living cell dynamic detector.
3) Culture supernatants were taken around 24h to detect LDH to calculate tumor lysis.
The experimental results are shown in fig. 3-9.
Figure 3 shows that tumor lysis gradually increased with increasing effective target ratio, demonstrating that CAR-T cells exert greater killing efficacy with increasing effective target ratio.
Figures 4-9 show the continuous killing effect at different effective target ratios. It can be seen that even at an effective Target ratio (also called E/T ratio), E: t=1:1 (E stands for Effector cell, i.e. Effector cell; T stands for Target cell, i.e. tumor cell), the number of cells in the field of view after 24 hours of continuous killing was significantly smaller than that of the control group. The CAR-T cells synthesized by the invention have obvious killing effect on tumor cells positively expressed by HER 2; while the control SHP2N+C-SH 2T cells alone hardly exert an antitumor effect. In addition, the CAR-T can maintain the killing efficacy for 48 hours continuously, which shows that the efficacy has better persistence.
The embodiments of the present invention have been described above with reference to the accompanying drawings, but the present invention is not limited to the above-described embodiments, which are merely illustrative and not restrictive, and many forms may be made by those having ordinary skill in the art without departing from the spirit of the present invention and the scope of the claims, which are to be protected by the present invention.
Claims (4)
1. A CAR-T targeting a HER2 positive expressing solid tumor, the chimeric antigen receptor portion of which comprises an extracellular domain, a transmembrane domain, and an intracellular domain, wherein the extracellular domain is a nanobody targeting a HER2 positive expressing solid tumor, and the intracellular domain comprises a synthetic SHP2 protein domain; the synthesized SHP2 protein domain is an N+C-SH2 domain, and the nucleotide sequence of the domain is shown as SEQ ID NO. 1; the intracellular domain of the chimeric antigen receptor further comprises a 4-1BB costimulatory molecule and a CD3ζ truncated signaling domain; the nucleotide sequence of the chimeric antigen receptor is shown as SEQ ID NO. 2.
2. Use of the CAR-T of claim 1 for the preparation of an anti-solid tumor drug, wherein the shp2n+c-SH 2 domain in the CAR-T is used to competitively bind to PD-1, blocking the transmission of PD-1 and/or PD-L1 immunosuppressive signals.
3. The use of claim 2, wherein the solid tumor comprises ovarian, breast, gastric or intestinal cancer.
4. The method of preparing CAR-T according to claim 1, comprising the steps of:
1) Synthesizing a CAR structure comprising a nanobody targeting a HER2 positive expressing solid tumor, a CD8 hinge region, a transmembrane region, a 4-1BB co-stimulatory molecule, a cd3ζ truncated signaling domain, and a shp2n+c-SH 2 domain, wherein the primer sequence for amplifying the shp2n+c-SH 2 domain shown in SEQ ID NO:1 is as set forth in SEQ ID NO:3 and SEQ ID NO:4 is shown in the figure;
2) Respectively carrying out double enzyme digestion on a plasmid vector and a synthesized CAR structure sequence by using restriction enzymes, carrying out transformation and screening culture after being connected by using T4 ligase, and carrying out sequencing identification on the obtained positive clone;
3) Expressing the CAR structural sequence synthesized in step 2) with T cells.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310627430.5A CN116376844B (en) | 2023-05-31 | 2023-05-31 | HER2 positive tumor targeting CAR-T containing SHP2 SH2 domain, preparation method and application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310627430.5A CN116376844B (en) | 2023-05-31 | 2023-05-31 | HER2 positive tumor targeting CAR-T containing SHP2 SH2 domain, preparation method and application |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116376844A CN116376844A (en) | 2023-07-04 |
CN116376844B true CN116376844B (en) | 2023-08-11 |
Family
ID=86971364
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310627430.5A Active CN116376844B (en) | 2023-05-31 | 2023-05-31 | HER2 positive tumor targeting CAR-T containing SHP2 SH2 domain, preparation method and application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116376844B (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021143695A1 (en) * | 2020-01-13 | 2021-07-22 | 广东泰禾医药科技有限公司 | Anti-tumor fusion protein, preparation method therefor and application thereof |
WO2022173703A1 (en) * | 2021-02-10 | 2022-08-18 | The Regents Of The University Of California | Immune receptors with synthetic co-stimulatory domains |
CN115427451A (en) * | 2020-02-14 | 2022-12-02 | 北京永泰瑞科生物科技有限公司 | Immune cell overexpressing externally introduced cell signal regulatory factor and use thereof |
WO2023060253A1 (en) * | 2021-10-08 | 2023-04-13 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201507688VA (en) * | 2013-03-15 | 2015-10-29 | Sloan Kettering Inst Cancer | Compositions and methods for immunotherapy |
US20200188434A1 (en) * | 2017-05-15 | 2020-06-18 | Autolus Limited | A cell comprising a chimeric antigen receptor (car) |
CA3207958A1 (en) * | 2021-02-16 | 2022-08-25 | Julyun OH | Compositions and methods for treating her2 positive cancers |
-
2023
- 2023-05-31 CN CN202310627430.5A patent/CN116376844B/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021143695A1 (en) * | 2020-01-13 | 2021-07-22 | 广东泰禾医药科技有限公司 | Anti-tumor fusion protein, preparation method therefor and application thereof |
CN115427451A (en) * | 2020-02-14 | 2022-12-02 | 北京永泰瑞科生物科技有限公司 | Immune cell overexpressing externally introduced cell signal regulatory factor and use thereof |
WO2022173703A1 (en) * | 2021-02-10 | 2022-08-18 | The Regents Of The University Of California | Immune receptors with synthetic co-stimulatory domains |
WO2023060253A1 (en) * | 2021-10-08 | 2023-04-13 | Revolution Medicines, Inc. | Ras inhibitors |
Non-Patent Citations (1)
Title |
---|
"Homo sapiens protein tyrosine phosphatase non-receptor type 11 (PTPN11), transcript variant 1, mRNA";Sun等;《GenBank》;Accession:NM_002834.5 * |
Also Published As
Publication number | Publication date |
---|---|
CN116376844A (en) | 2023-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105087495B (en) | T lymphocyte that two Chimeric antigen receptor is modified and preparation method thereof | |
EP3597742B1 (en) | Car expression vector and car-expressing t cells | |
CN108384760B (en) | Human T lymphocyte carrying CD20/CD19 bispecific chimeric antigen receptor and preparation method and application thereof | |
CN105567641B (en) | A kind of preparation method and applications carrying anti-tumor protein targeting exosome | |
CN109722437B (en) | Universal CAR-T cell and preparation method and application thereof | |
US20210154231A1 (en) | Method for producing t cells modified by chimeric antigen receptor | |
CN110172479B (en) | Plasmid capable of simultaneously expressing LMP1 and CD30 double-target CAR, CAR-T cell, construction method and application thereof | |
CN111748044B (en) | CD19 and PD-L1 double-target chimeric antigen receptor and application thereof | |
CN110183537B (en) | EGFR specific chimeric antigen receptor, coding gene, CAR-T cell, preparation method, recombinant cell and application thereof | |
CN110343665B (en) | CAR-T cell and application thereof | |
CN112029729B (en) | CD19 and CD22 double-target chimeric antigen receptor NK (natural killer) cell and application thereof | |
CN111484559B (en) | Construction and application of third generation NKG2D chimeric antigen receptor T or NK cell | |
CN112391414A (en) | HER 2-targeted CAR-T expression vector and construction and application thereof | |
CN113621077B (en) | TIM-3/CD28 fusion protein and CAR-T cell modified by fusion protein | |
CN116376844B (en) | HER2 positive tumor targeting CAR-T containing SHP2 SH2 domain, preparation method and application | |
CN116355859B (en) | HER2 positive tumor targeting CAR-T containing SHP 2N-SH 2 domain, preparation method and application | |
CN116655806B (en) | HER2 positive tumor targeting CAR-T containing SHP2C-SH 2domain, preparation method and application | |
CN113583143A (en) | CAR-T cells and methods of making the same | |
CN108753773A (en) | Interfere CD19-CAR-T cells and its application of IFN-gama expression | |
CN116478931A (en) | High-affinity anti-tumor NK cell and preparation method and application thereof | |
CN116655805B (en) | Novel CAR-T cell targeting HER2 positive tumor, preparation method and application | |
CN116396385A (en) | anti-BCMA nano antibody and preparation method and application thereof | |
CN112226412B (en) | T cell expressing immunosuppressive checkpoint receptor molecule and application thereof | |
CN110484507B (en) | Preparation technology of novel chimeric antigen receptor T cells for targeting tumor Her2 | |
CN113735981A (en) | CD19-CAR-T cell and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |